EWTX - Edgewise Therapeutics proposes $100M stock offering plan
- Edgewise Therapeutics ( NASDAQ: EWTX ) announced Tuesday its plans to raise $100M in the underwritten public stock offering; price, size and other terms not yet determined.
- The Colorado-based biopharmaceutical company told underwriters will be granted an overallotment option to purchase up to an additional $15M shares.
- It comes right after Edgewise Therapeutics received FDA's approval for phase 2 trial of its experimental drug, EDG-5506, in children with muscular dystrophy.
- Stock is down 2% in pre-market trading.
For further details see:
Edgewise Therapeutics proposes $100M stock offering plan